New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
06:33 EDTCYTRCytRx begins Phase 2 clinical trial with aldoxorubicin for Kaposi's sarcoma
CytRx has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposiís sarcoma. The primary objective of preliminary efficacy will be determined through evaluation of the size, number and nodularity of skin lesions, and the company will evaluate the level of aldoxorubicin uptake into lesions. CytRx plans to discuss a pathway for the registration of aldoxorubicin for KS with the FDA if the data are positive. The company expects to announce data from this Phase 2 clinical trial in Q2 2015.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
09:04 EDTCYTRCytRx's aldoxorubicin shows positive Phase 2 results for brain cancer
CytRx announced positive updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme, a deadly form of brain cancer. The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide. 18 study subjects have received between 1 and 14 cycles of aldoxorubicin, with 4 subjects continuing to receive aldoxorubicin treatment. 2 subjects diagnosed with tumor progression following aldoxorubicin treatment demonstrated no microscopic evidence of tumor tissue after resection. Fourteen of 18 subjects discontinued aldoxorubicin treatment, although there is a significant possibility that some of the patients experienced pseudo-progression. Following discontinuation of aldoxorubicin treatment, 10 of 14 subjects received treatment with bevacizumab for 1 to 14 cycles. Deaths have occurred in only 4 of 18 subjects to date, with survival duration so far of up to 10 plus months. Aldoxorubicin was well tolerated at both dose levels with all adverse events consistent with known doxorubicin toxicities, but not cardiotoxity.
May 12, 2015
09:36 EDTCYTRCytRx management to meet with Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use